United Laboratories Sets Out Board and Committee Structure

The United Laboratories International Holdings ( (HK:3933) ) has provided an update.

The United Laboratories International Holdings Limited has outlined the composition of its board of directors, naming its executive and independent non-executive members and confirming key leadership roles such as chairman and vice-chairman. The company also detailed the membership of its five board committees—Audit, Remuneration, Nomination, Risk Management, and Sustainability—clarifying oversight responsibilities that are important for corporate governance and risk control.

Several independent non-executive directors, including Chong Peng Oon, Prof. Song Ming, and Dr. Fu Qiushi, hold multiple committee positions, underscoring the emphasis on independent oversight in financial reporting, remuneration, and risk management. The inclusion of executive directors on the Nomination, Risk Management, and Sustainability Committees further integrates management and board-level supervision, which may enhance accountability and align strategic, risk, and sustainability priorities for shareholders and other stakeholders.

The most recent analyst rating on (HK:3933) stock is a Buy with a HK$20.00 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.

More about The United Laboratories International Holdings

The United Laboratories International Holdings Limited is a Cayman Islands-incorporated pharmaceutical company listed in Hong Kong. It operates in the drug manufacturing sector, with a governance structure that includes executive directors and independent non-executive directors overseeing its strategic and regulatory responsibilities.

Average Trading Volume: 9,804,960

Technical Sentiment Signal: Hold

Current Market Cap: HK$18.7B

Find detailed analytics on 3933 stock on TipRanks’ Stock Analysis page.